Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gastrointestinal pathology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    57 result(s) found for: Gastrointestinal pathology. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-001372-37 Sponsor Protocol Number: ET13-024 Start Date*: 2014-06-13
    Sponsor Name:CENTRE LEON BERARD
    Full Title: A randomized, multicentre, phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tu...
    Medical condition: GastroIntestinal Stromal Tumours (GIST)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001547-43 Sponsor Protocol Number: ET19-075 Start Date*: 2022-01-18
    Sponsor Name:Centre Léon Bérard
    Full Title: ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectabl...
    Medical condition: Unresectable locally advanced or metastatic gastrointestinal stromal tumors (GIST) after failure of standard treatments
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001803-35 Sponsor Protocol Number: DCC-2618-03-002 Start Date*: 2019-04-01
    Sponsor Name:Deciphera Pharmaceuticals, LLC
    Full Title: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
    Medical condition: Patients with Advanced Gastrointestinal Stromal Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) CZ (Completed) NO (Trial now transitioned) ES (Ongoing) SE (Completed) BE (Completed) NL (Trial now transitioned) HU (Completed) PL (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002524-16 Sponsor Protocol Number: 240562-2013-01 Start Date*: 2014-01-10
    Sponsor Name:Dept of Oncology. Haukeland University Hospital
    Full Title: Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%
    Medical condition: Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001930-26 Sponsor Protocol Number: LEOC/FJD-14/01 Start Date*: 2014-10-10
    Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
    Full Title: A randomized, evaluator blinded clinical trial to compare clinical efficacy of four different analgesic strategies in patients undergoing Extracorporeal Shock Wave Lithotripsy (ESWL).
    Medical condition: Pain in Nephrolithiasis in whom Extracorporeal shock wave lithotripsy is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10017926 Gastrointestinal and abdominal pains (excl oral and throat) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003168-37 Sponsor Protocol Number: Thllo Start Date*: 2019-05-13
    Sponsor Name:University Tuebingen
    Full Title: Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study
    Medical condition: Acute respiratory distress syndrome requiring mechanical ventilation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005255-87 Sponsor Protocol Number: 2014-13 Start Date*: 2016-05-04
    Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE
    Full Title: Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.
    Medical condition: Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002586-34 Sponsor Protocol Number: STEROID_MC_1 Start Date*: 2020-11-12
    Sponsor Name:Department of Anesthesiology, Copenhagen University Hospital Hvidovre, Capital Region of Denmark
    Full Title: The effects of preoperative high-dose Dexamethasone on inflammatory response and recovery after emergency laparotomy, a randomized, double-blind, placebo-controlled clinical trial - AHA STEROID ...
    Medical condition: Patients undergoing emergency laparotomy due to either Intestinal obstruction or perforated abdominal viscus.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10053361 Explorative laparotomy PT
    20.1 10018065 - General disorders and administration site conditions 10051379 Systemic inflammatory response syndrome PT
    22.0 10017947 - Gastrointestinal disorders 10021328 Ileus PT
    20.0 10017947 - Gastrointestinal disorders 10034406 Perforation bowel LLT
    20.0 10017947 - Gastrointestinal disorders 10034430 Perforation stomach LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001185-32 Sponsor Protocol Number: 38/2007/O/Sper Start Date*: 2007-03-28
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Protocol for the experimental study about Peritonectomy (CCR) associated with Chemo-Hyperthermic intra-peritonel (CHIP) treatment for primary or secondary peritoneal neoplastic desease (Peritoneal ...
    Medical condition: Peritoneal Carcinosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000069-34 Sponsor Protocol Number: PAMORA_2020_RAP Start Date*: 2021-11-19
    Sponsor Name:Mech-Sense, Aalborg University Hospital
    Full Title: Effects of a peripherally acting μ-opioid receptor antagonist on recurrent acute pancreatitis: An investigator-initiated, randomized, placebo-controlled, double-blind clinical trial
    Medical condition: Recurrent acute pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10033647 Pancreatitis acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022894-32 Sponsor Protocol Number: RG_10-209 Start Date*: 2011-02-16
    Sponsor Name:University of Birmingham
    Full Title: Dexamethasone Reduces Emesis After Major gastrointestinal Surgery (DREAMS trial) - A prospective, double-blind, multicentre, randomised control trial
    Medical condition: Patients undergoing nausea and vomiting following elective colorectal resections
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004837-16 Sponsor Protocol Number: CRAD001C2454 Start Date*: 2006-10-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST
    Medical condition: gastrointestinal stromal tumors (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002288-24 Sponsor Protocol Number: Ci-FCP001 Start Date*: 2021-08-10
    Sponsor Name:Amsterdam UMC
    Full Title: Effect of citalopram on chest pain in patients with functional chest pain
    Medical condition: Chest pain can be divided in cardiac or non-cardiac chest pain (NCCP). To establish the diagnosis NCCP, acute coronary disease has to be ruled out first. NCCP can be caused by functional chest pain...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000171-13 Sponsor Protocol Number: P23 Start Date*: 2023-08-23
    Sponsor Name:leiden university medical center
    Full Title: SGM-101 tumor-targeted fluorescence endoscopy to enable discrimination of malignant from benign tissue in rectal polyps with suspected T1 adenocarcinoma or high grade dysplasia: a feasibility study
    Medical condition: Early rectal cancer/ big polyps with suspected T1 rectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10017947 - Gastrointestinal disorders 10038074 Rectal polyp PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002522-36 Sponsor Protocol Number: CPDR001E2201 Start Date*: 2016-12-29
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin...
    Medical condition: Advanced neuroendocrine tumor (NET) of pancreatic, GI lung origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003070-33 Sponsor Protocol Number: DANSAC-RCT Start Date*: 2015-11-30
    Sponsor Name:Odense University Hospital
    Full Title: DANSAC-RCT: Fosaprepitant in patients with advanced cancer not receiving chemotherapy or irradiation; A multicenter, randomized, double-blind, placebo-controlled study.
    Medical condition: Emesis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10028817 Nausea and vomiting symptoms HLT
    18.1 10017947 - Gastrointestinal disorders 10014542 Emesis LLT
    18.1 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001234-17 Sponsor Protocol Number: A3191084 Start Date*: 2006-06-15
    Sponsor Name:Pfizer Limited
    Full Title: Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in su...
    Medical condition: Treatment of osteoarthritis (OA) and/or rheumatoid arthritis (RA) in high GI risk patients
    Disease: Version SOC Term Classification Code Term Level
    8.0 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed) SE (Completed) CZ (Completed) LT (Completed) DE (Suspended by CA) EE (Completed) PT (Completed) GR (Completed) IE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2017-001263-20 Sponsor Protocol Number: D-FR-01087-001 Start Date*: 2018-12-18
    Sponsor Name:Ipsen Pharma SAS
    Full Title: An International Multicentre, Open-Label First in Human Phase I/II study to evaluate the safety, tolerability, biodistribution and antitumour activity of 177Lu-3BP-227 for the treatment of subjects...
    Medical condition: Patients with unresecable, metastatic or locally advanced cancers expressing Neurotensin Receptor 1 (NTSR1).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003402-40 Sponsor Protocol Number: XL184-401 Start Date*: 2015-06-16
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
    Medical condition: Progressive Metastatic Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Completed) ES (Ongoing) FR (Completed) PL (Trial now transitioned) HU (Trial now transitioned) HR (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004277-17 Sponsor Protocol Number: 2008/2 Start Date*: 2010-05-10
    Sponsor Name:GlobiFer International bvba
    Full Title: The effectiveness and tolerability of GlobiFer (haem iron) tablets compared to ferrous sulphate tablets in inflammatory bowel disease: a randomised-controlled trial.
    Medical condition: Anaemia in inflammatory bowel disease
    Disease:
    Population Age: Adolescents, Under 18, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Dec 07 15:11:11 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA